JOYN Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

JOYN Advisors’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-90	Closed	-$1K	–	1647
2018 Q4	$1K	Buy	90 +5	+6%	+$70	﹤0.01%	1705
2018 Q3	$2K	Hold	85	–	–	﹤0.01%	1527
2018 Q2	$2K	Buy	+85	New	+$1.82K	﹤0.01%	1486

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JOYN Advisors's MNTA Position: Q1 2019 in Review

JOYN Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2019, closing a stake of 90 shares — an estimated $1K sold.

JOYN Advisors first reported a position in MNTA in Q2 2018 and held it in 3 quarters. The position peaked at $2K in Q3 2018. 147 funds tracked by Wall St. Rank hold MNTA as of Q1 2019.

JOYN Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
JOYN Advisors sold 90 Momenta Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1K.
JOYN Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
JOYN Advisors's Momenta Pharmaceuticals, Inc. position peaked at $2K in Q3 2018.
147 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2019.

Based on JOYN Advisors's 13F filing for Q1 2019, filed 9 May 2019.